Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.
about
Structural and Computational Biology in the Design of Immunogenic Vaccine AntigensAntibody-Based Strategies to Prevent and Treat InfluenzaVaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesOriginal Antigenic Sin Response to RNA Viruses and Antiviral ImmunityReverse Genetics Approaches for the Development of Influenza VaccinesReplication-competent fluorescent-expressing influenza B virusSynthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responsesAn Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.Is it possible? A different approach to creating a universal influenza vaccine.Novel universal influenza virus vaccine approachesUniversal influenza vaccines: Shifting to better vaccines.Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.High preexisting serological antibody levels correlate with diversification of the influenza vaccine responsePhysical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunityDownregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines.Universal Influenza Vaccines: To Dream the Possible Dream?Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.Reassortment in segmented RNA viruses: mechanisms and outcomes.Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies.From Original Antigenic Sin to the Universal Influenza Virus Vaccine.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.Heterosubtypic cross-reactivity of HA1 antibodies to influenza A, with emphasis on nonhuman subtypes (H5N1, H7N7, H9N2).Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States.Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology.Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines.Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.Towards the Application of Human Defensins as Antivirals.Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.The Global Influenza Surveillance and Response System (GISRS) - A Future Perspective.Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies.Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization.Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy.Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections
P2860
Q26777382-6FD9FFAB-2395-4B2B-9698-B20E0BEB25F0Q26798520-01B1DD41-B23F-4E98-BC49-EED802D5D77EQ27644544-32BDF854-D273-40A8-AECE-C749F6C17449Q28066918-E4664D21-9935-4E08-B598-165ECA44444DQ28076140-9EA604BA-CE36-426C-B1A8-53E94688685FQ28387786-83DDECF9-582C-445C-88CA-541B467012C7Q30205195-EDF0ACE8-433C-4420-89CD-FA020DBEC2F8Q30377023-831BB5E5-0AA3-4587-A805-BE3CD8969609Q30380050-90D42D90-9B58-453C-8441-693D75DCC998Q30385071-5F54B407-7187-4B08-B1B6-66CD4E63B56FQ30386388-5DF20EE3-6379-4BE1-89BE-6BD87D368C63Q30387031-49FFBDA9-411E-452D-8A03-37E6C4207C7CQ30398228-B4109C63-3B93-40D9-B0A3-CBB16EE01464Q34594065-CBA3810E-12B3-48CE-9C14-E55D2C8D7F65Q35110980-5A637DE1-D068-454F-A3C7-16A439C82F6FQ35128920-8C5E42F1-296C-44D5-A4F7-F6C9CE2585B1Q35869278-0F9B2B94-A92E-4227-B611-F3A2AF458476Q36675360-903C7518-4576-44E3-B6CB-CD4CC899AC72Q37323172-91C7F86A-6FC2-4C85-8DDC-6CC1472F4093Q37428960-AFCFCACE-A3DA-47FB-A665-1A39C0E55CC3Q40057948-B72F9C41-1057-4982-A9AA-35A173CE3812Q40059787-AAB538ED-68E0-4ABE-916F-5A5987A8B7C2Q40116011-CDC70A8D-EFA3-44D2-8F85-73A703E22686Q40120056-904747C6-AD37-4565-A086-E8182F6A95BEQ40139850-DCC4DB78-BEFB-488B-87DD-66B779708451Q40491281-A5623E4D-951D-4461-B644-E2C6E53B458EQ40529074-81A7E8B5-DE13-49C7-A8E7-8AC3EBF94D02Q40577440-E99ABD8C-5698-4969-8774-86487B3FA818Q41919718-9D6DC212-47FC-4340-B08E-CC2F38E0756DQ45324976-CA181A92-9686-40BA-8166-0221940EABEDQ45951581-AE8D8893-00D0-439D-9829-2F17DB1B3F2CQ47117776-00E34D69-BA99-4FF4-AFDB-C7D25A164351Q47150783-BD2C8476-A500-4495-AF18-930B3E95CD98Q47557198-8A2EA901-025A-4066-8D29-B150ABAC8589Q50533261-0AAAA4C3-804B-4810-ADDB-492E1D842853Q54222152-91923DD2-5E6A-4E74-B293-07C42AA00F9BQ54979433-E3A49889-D7B1-45C8-9FE6-A7F629D66688Q55627667-3644DC54-9BEE-4650-95AA-E5FEB1F060E9Q55689231-C816F822-41F8-47F7-832C-2F4C87664AE9Q57167166-D60EC26D-FA24-4A3B-AF93-D3B600FDB610
P2860
Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Advances in universal influenz ...... regions of the hemagglutinin.
@ast
Advances in universal influenz ...... regions of the hemagglutinin.
@en
type
label
Advances in universal influenz ...... regions of the hemagglutinin.
@ast
Advances in universal influenz ...... regions of the hemagglutinin.
@en
prefLabel
Advances in universal influenz ...... regions of the hemagglutinin.
@ast
Advances in universal influenz ...... regions of the hemagglutinin.
@en
P356
P1476
Advances in universal influenz ...... regions of the hemagglutinin.
@en
P2093
John Steel
P304
P356
10.1007/82_2014_408
P577
2015-01-01T00:00:00Z